The drug pricing regulator has slashed retail prices of 543 formulations across 137 non-scheduled cancer medicines, with some cuts exceeding 90% under a trade margin rationalisation framework.
The drug pricing regulator has slashed retail prices of 543 formulations across 137 non-scheduled cancer medicines, with some cuts exceeding 90% under a trade margin rationalisation framework. by Soban News (international And National News)
